Cargando…

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Despite current therapies, there remains an unmet need for treatment for patients with hemophilia. The main parts of two phase 2 trials established clinical proof-of-concept for once-daily, subcutaneous concizumab prophylaxis in patients with hemophilia A/B with inhibitors (HAwI/HBwI; explorer4) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapiro, Amy D., Angchaisuksiri, Pantep, Astermark, Jan, Benson, Gary, Castaman, Giancarlo, Eichler, Hermann, Jiménez-Yuste, Victor, Kavakli, Kaan, Matsushita, Tadashi, Poulsen, Lone Hvitfeldt, Wheeler, Allison P., Young, Guy, Zupančić-Šalek, Silva, Oldenburg, Johannes, Chowdary, Pratima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198939/ https://www.ncbi.nlm.nih.gov/pubmed/35290453 http://dx.doi.org/10.1182/bloodadvances.2021006403

Ejemplares similares

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data
por: Eichler, Hermann, et al.
Publicado: (2018)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives
por: Pasca, Samantha
Publicado: (2022)

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
por: Chuansumrit, Ampaiwan, et al.
Publicado: (2010)

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
por: Chowdary, Pratima
Publicado: (2018)

Prospective Evaluation of Non-Compliant Severe Hemophilia Patients
por: Uğur, Mehmet Can, et al.
Publicado: (2019)

Practices and challenges for hemophilia management under resource constraints in Thailand
por: Moonla, Chatphatai, et al.
Publicado: (2023)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study
por: Van Der Valk, Paul, et al.
Publicado: (2022)

Considerations for shared decision management in previously untreated patients with hemophilia A or B
por: Astermark, Jan, et al.
Publicado: (2023)

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019)

Hemophilia A and B: molecular and clinical similarities and differences
por: Castaman, Giancarlo, et al.
Publicado: (2019)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers
por: Gooding, Richard, et al.
Publicado: (2021)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients
por: Fidancı, İnanç Değer, et al.
Publicado: (2014)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
por: Manderstedt, Eric, et al.
Publicado: (2020)

Activation of the Acute-Phase Response in Hemophilia
por: Knowles, Lynn M., et al.
Publicado: (2023)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs
por: Castaman, Giancarlo, et al.
Publicado: (2023)

Hemophilia of orbit
por: Karunanithi, Gunaseelan, et al.
Publicado: (2009)

Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014)

Treatment of Hemophilia
Publicado: (1896)

Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
por: Astermark, Jan, et al.
Publicado: (2023)

ESTIMATION OF THE GLOMERULAR FILTRATION RATE IN CHILDREN WITH HEMOPHILIA
por: Šalek, Zrinko, et al.
Publicado: (2022)

A Case of Acquired Hemophilia A and Congenital Hemophilia B
por: Fortier, Julia C, et al.
Publicado: (2022)

Managing Relevant Clinical Conditions of Hemophilia A/B Patients
por: Morfini, Massimo, et al.
Publicado: (2023)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
por: Ay, Cihan, et al.
Publicado: (2023)

4084 Predictors of mortality among non-severe hemophilia A patients in the United States
por: Lim, Ming Y, et al.
Publicado: (2020)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2016)

Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses
por: Demartis, Francesco, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hare3892u0bsm5t6qlii6kc7qn